Paratek Phase IIb data shows omadacycline’s potential to address unmet needs in NTM treatment, says… GlobalData Nov 15, 2024 The placebo-controlled trial enrolled 66 patients with NTM pulmonary disease caused by MABc. In the study, oral omadacycline was…
Sun Pharma presents data from first-in-human phase 1 studies of GL0034 EP News Bureau Jun 28, 2023 GL0034 (utreglutide) is an investigational novel glucagon-like peptide 1 receptor agonist (GLP- 1RA) in development as a…
